Paper Details

  1. Home
  2. Paper Details

A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization.

Author: BossieCynthia A, BurteaVictoria, DavidsonMichael, GharabawiGeorges M, GreenspanAndrew J, Kosik-GonzalezColette, MahmoudRamy, PotkinSteven G, RupnowMarcia F T, TrivediJintendra K, ZhuYoung

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Risperidone was more effective than placebo in improving symptoms of schizophrenia in recently hospitalized patients. However, both risperidone and quetiapine were associated with side effects, including weight gain, sedation, and movement disorders.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: This study compared the effects of atypical antipsychotics (risperidone or quetiapine) with placebo and with each other in recently exacerbated patients with schizophrenia requiring hospitalization. METHODS: This international, randomized, double-blind study included a 2-week monotherapy...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.schres.2006.03.027

データ提供：米国国立医学図書館（NLM）

Comparing Atypical Antipsychotics in Hospitalized Schizophrenia Patients

This research delves into the world of [schizophrenia treatment], a field where finding effective and safe medications is a constant quest. This study used a [double-blind randomized controlled trial] to compare the effectiveness of two atypical antipsychotics, [risperidone and quetiapine], with [placebo] in patients experiencing an [acute exacerbation of schizophrenia] requiring hospitalization. The researchers discovered that [risperidone] showed significant superiority to placebo in managing the symptoms of schizophrenia, while [quetiapine] did not.

Risperidone's Promise in Schizophrenia Management

The findings suggest that [risperidone] holds promise as a treatment for patients with [schizophrenia] who are experiencing an acute exacerbation of their symptoms. The study's results, which show that [risperidone] significantly outperformed placebo in reducing the severity of symptoms, are encouraging for those seeking effective treatments for this complex disorder.

Navigating Schizophrenia Treatment

It's important to remember that [schizophrenia] is a complex disorder, and there is no one-size-fits-all treatment approach. These findings provide a valuable piece of the puzzle, highlighting the potential benefits of [risperidone] in managing acute episodes. It's essential for individuals with [schizophrenia] to consult with their doctors to determine the most appropriate treatment plan for their individual needs.

Dr.Camel's Conclusion

Just like the desert can be harsh and unforgiving, schizophrenia can be a challenging journey. However, the results of this study offer a glimmer of hope, suggesting that risperidone may be a beacon of relief for those navigating this challenging landscape. It reminds us that even in the most desolate landscapes, there can be pockets of healing and progress.

Date :
  1. Date Completed 2006-12-28
  2. Date Revised 2016-05-26
Further Info :

Pubmed ID

16797162

DOI: Digital Object Identifier

10.1016/j.schres.2006.03.027

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.